Defined as diabetic ketoacidosis with plasma glucose levels < 300 mg/dL, euDKA occurs in patients on SGLT2 inhibitors due to a potent augmentation of the urinary glucose clearance rate. Here, SLC5A2 is linked to diabetic ketoacidosis.